Roche News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

29.10.19	Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. (GlobeNewswire)
21.10.19	Roche’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma (GlobeNewswire)
18.10.19	Roche announces FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications (GlobeNewswire)
16.10.19	Roche mit sehr gutem Verkaufswachstum in den ersten neun Monaten 2019 – Ausblick angehoben (GlobeNewswire)
16.10.19	Roche reports very strong sales growth in the first nine months of 2019 – outlook raised (GlobeNewswire)
14.10.19	Phase III PEMPHIX study shows Roche’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris (GlobeNewswire)
30.09.19	Roche presents positive Phase III results for Tecentriq® (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer (GlobeNewswire)
30.09.19	Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa (GlobeNewswire)
30.09.19	FDA approves Roche’s Rituxan (rituximab) in children with two rare blood vessel disorders (GlobeNewswire)
30.09.19	Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. (GlobeNewswire)
28.09.19	Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer (GlobeNewswire)
27.09.19	Roche's Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer (GlobeNewswire)
27.09.19	Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma (GlobeNewswire)
23.09.19	Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress (GlobeNewswire)
20.09.19	FDA approves cobas Babesia, Roche’s first whole blood test for donor screening (GlobeNewswire)
19.09.19	Roche renews its commitment to the primary healthcare Phelophepa trains, marking the 25th anniversary (GlobeNewswire)
19.09.19	Roche erneuert zum 25-jährigen Bestehen des ersten Phelophepa-Zugs sein Engagement (GlobeNewswire)
18.09.19	FDA grants Breakthrough Therapy Designation for Roche’s Gazyva (obinutuzumab) in Lupus Nephritis (GlobeNewswire)
16.09.19	Roche ranked as one of the most sustainable healthcare companies in the Dow Jones Sustainability Indices for the eleventh year running (GlobeNewswire)
16.09.19	Roche zum elften Mal in Folge als eines der nachhaltigsten Gesundheitsunternehmen im Dow Jones Sustainability Index ausgezeichnet (GlobeNewswire)
16.09.19	Roche receives FDA clearance for cobas pro integrated solutions designed to help labs deliver faster results to patients (GlobeNewswire)
13.09.19	Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis (GlobeNewswire)
13.09.19	Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer (GlobeNewswire)
12.09.19	Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum (GlobeNewswire)
12.09.19	Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy (GlobeNewswire)
10.09.19	Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS (GlobeNewswire)
06.09.19	European Commission approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer (GlobeNewswire)
06.09.19	European Commission approves Roche’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer (GlobeNewswire)
04.09.19	Roche to present pivotal data for satralizumab in neuromyelitis optica spectrum disorder and six-year OCREVUS data in multiple sclerosis at ECTRIMS (GlobeNewswire)
03.09.19	Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. (GlobeNewswire)
02.09.19	Positive phase III results show Xofluza reduces risk of developing flu after contact with an infected person by 86% (GlobeNewswire)
02.09.19	Roche presents positive phase III study results for one-dose Xofluza in children with flu (GlobeNewswire)
29.08.19	Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq (GlobeNewswire)
29.08.19	European Commission approves Roche’s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer (GlobeNewswire)
16.08.19	FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours (GlobeNewswire)
05.08.19	Roche’s Tecentriq plus platinum-based chemotherapy reduced the risk of disease worsening or death in people with previously untreated advanced bladder cancer (GlobeNewswire)
31.07.19	Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. (GlobeNewswire)
26.07.19	Roche receives CHMP positive opinion for new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer (GlobeNewswire)
26.07.19	CHMP recommends EU approval of Roche’s Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer (GlobeNewswire)
25.07.19	Roche reports very strong performance in the first half of 2019 – Outlook raised (GlobeNewswire)
25.07.19	Roche mit sehr gutem Ergebnis im ersten Halbjahr 2019 – Ausblick angehoben (GlobeNewswire)
22.07.19	Roche expands the Global Access Program beyond HIV to also include diagnostic tests for Tuberculosis, Hepatitis, and Human Papillomavirus (GlobeNewswire)
22.07.19	Roche erweitert globales Zugangsprogramm über HIV hinaus auf diagnostische Tests für Tuberkulose, Hepatitis und humanes Papillomavirus (GlobeNewswire)
09.07.19	Roche presents a broad range of data for Hemlibra demonstrating continued benefits for people with haemophilia A at the ISTH 2019 Congress (GlobeNewswire)
28.06.19	CHMP recommends EU approval of Roche’s Tecentriq in combination with Abraxane as an initial treatment for people with PD-L1-positive, metastatic triple-negative breast cancer (GlobeNewswire)
18.06.19	Japan becomes the first country to approve Roche’s personalised medicine Rozlytrek (GlobeNewswire)
11.06.19	FDA grants Roche’s Polivy accelerated approval for people with previously treated aggressive lymphoma (GlobeNewswire)
11.06.19	Changes in Roche's Board of Directors and Corporate Executive Committee (GlobeNewswire)
11.06.19	Änderungen im Verwaltungsrat und in der Konzernleitung von Roche (GlobeNewswire)
10.06.19	Roche and Spark Therapeutics, Inc. receive Request for Additional Information from FTC under Hart-Scott-Rodino Act and announce extension of tender offer for shares of Spark Therapeutics, Inc. (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20:03		Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones
18:01		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
17:58		Handel in Europa: STOXX 50 schliesst im Minus
17:58		Schwacher Handel: SMI schliesst mit Verlusten
17:58		Verluste in Europa: Euro STOXX 50 letztendlich leichter
17:58		SPI-Handel aktuell: SPI zum Handelsende leichter
17:58		Minuszeichen in London: FTSE 100 schwächelt zum Ende des Freitagshandels
15:58		SPI-Handel aktuell: SPI verliert